ไม่สามารถเล่นวิดีโอนี้
ขออภัยในความไม่สะดวก
A New Norm for Skin Cancer Patients: Dale’s Immunotherapy Story
ฝัง
- เผยแพร่เมื่อ 31 พ.ค. 2018
- After Dale exhausted several treatment options for cutaneous squamous cell carcinoma, he enrolled in a clinical trial testing a PD-1 blocking antibody called cemiplimab. #CIM18 #CancerStories
Like many of us, Dale spent a lot of time in the sun and didn't think to protect his skin from harmful UV radiation. Years later, he developed scaly patches of actinic keratosis that later progressed to cutaneous squamous cell carcinoma, the second most common type of skin cancer. Surgeries, skin grafts, and chemotherapy failed to prevent Dale's tumors from spreading. Concerned about his future and having exhausted standard treatment options, Dale enrolled in a clinical trial testing a PD-1 blocking antibody called cemiplimab. Almost immediately his tumors began to disappear. Today, Dale has no evidence of cancer and is able to continue living his life with his wife, Donna, and his two children. www.cancerrese...
This video is presented as part of the Cancer Research Institute 6th Annual Cancer Immunotherapy Month awareness campaign this June 2018. Learn more about cancer immunotherapy and its potential to save more lives at www.cancerresea...
Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. www.cancerrese...
Dale. Your story and mine are almost identical. Diagonsed with CSCC Oct 2015. Declared terminal Nov 2016. Started phase 2 trial Dec 2016.Had 48 treatments Now all clear. Thank God for Regeneron, REGN 2810, cemiplimab Libtayo What ever you want to call it.
Omg they are really practicing mad science when immune therapy